NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy

American Journal of Physiology - Renal Physiology

Volumn 310, Issue 10, 2016, Pages F1081-F1088

  Gong, Wei ^a,b,c   Mao, Song ^a,b,c   Yu, Jing ^a,b,c   Song, Jiayu ^a,b,c   Jia, Zhanjun ^a,b,c   Huang, Songming ^a,b,c   Zhang, Aihua ^a,b,c  

^a CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Nanjing Key Laboratory of Pediatrics   (China)

Author keywords

Chronic kidney disease; Mitochondrial dysfunction; NLRP3 inflammasome

Indexed keywords

CRYOPYRIN; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; NLRP3 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CLINICAL EVALUATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXTRACELLULAR MATRIX; FIBROGENESIS; FLOW CYTOMETRY; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEPHRECTOMY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM; NEPHROSCLEROSIS; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; HYPERTENSION; MICE; MICE, INBRED C57BL; MITOCHONDRIAL DISEASES; NEPHRECTOMY; NEPHROSCLEROSIS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA;

EID: 84984597004     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00534.2015     Document Type: Article

References (29)

1. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 83: 1010-1016, 2013.
2. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 80: 915-925, 2011.
3. Arroyo DS, Gaviglio EA, Peralta Ramos JM, Bussi C, Rodriguez-Galan MC, Iribarren P. Autophagy in inflammation, infection, neurodegeneration and cancer. Int Immunopharmacol 18: 55-65, 2014
4. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Grone HJ, Schaefer L. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 284: 24035-24048, 2009.
5. Bello AK, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl S11-S17, 2005
6. Chen H, Zhu J, Liu Y, Dong Z, Liu H, Zhou X, Liu F, Chen G. Lipopolysaccharide induces chronic kidney injury and fibrosis through activation of mTOR signaling in macrophages. Am J Nephrol 42: 305-317, 2015.
7. Chen JF, Liu H, Ni HF, Lv LL, Zhang MH, Zhang AH, Tang RN, Chen PS, Liu BC. Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats. PLoS One 8: e83593, 2013.
8. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12, 2003.
9. Ding W, Xu C, Wang B, Zhang M. Rotenone attenuates renal injury in aldosterone-infused rats by inhibiting oxidative stress, mitochondrial dysfunction, and inflammasome activation. Med Sci Monit 21: 3136-3143, 2015.
10. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 12: 353-365, 2005.
11. Escamilla-Rivera V, Uribe-Ramirez M, Gonzalez-Pozos S, Lozano O, Lucas S, De Vizcaya-Ruiz A. Protein corona acts as a protective shield against FeO-PEG inflammation and ROS-induced toxicity in human macrophages. Toxicol Lett 240: 172-184, 2015.
12. Guo K, Lu J, Huang Y, Wu M, Zhang L, Yu H, Zhang M, Bao Y, He JC, Chen H, Jia W. Protective role of PGC-1alpha in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling. PLoS One 10: e0125176, 2015.
13. Jesinkey SR, Funk JA, Stallons LJ, Wills LP, Megyesi JK, Beeson CC, Schnellmann RG. Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury. J Am Soc Nephrol 25: 1157-1162, 2014.
14. Jones LK, O’Sullivan KM, Semple T, Kuligowski MP, Fukami K, Ma FY, Nikolic-Paterson DJ, Holdsworth SR, Kitching AR. IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol Dial Transplant 24: 3024-3032, 2009.
15. Lorenz G, Darisipudi MN, Anders HJ. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 29: 41-48, 2014.
16. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 27: 229-265, 2009.
17. Mattson DL. Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury. Am J Physiol Renal Physiol 307: F499-F508, 2014.
18. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB, Li PK. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 6: 133-141, 2011.
19. Medenwald D, Girndt M, Loppnow H, Kluttig A, Nuding S, Tiller D, Thiery JJ, Greiser KH, Haerting J, Werdan K. Inflammation and renal function after a four-year follow-up in subjects with unimpaired glomerular filtration rate: results from the observational, population-based CARLA cohort. PLoS One 9: e108427, 2014.
20. Peeri M, Amiri S. Protective effects of exercise in metabolic disorders are mediated by inhibition of mitochondrial-derived sterile inflammation. Med Hypotheses 85: 707-709, 2015.
21. Souza AC, Tsuji T, Baranova IN, Bocharov AV, Wilkins KJ, Street JM, Alvarez-Prats A, Hu X, Eggerman T, Yuen PS, Star RA. TLR4 mutant mice are protected from renal fibrosis and chronic kidney disease progression. Physiol Rep 3: e12558, 2015.
22. Su M, Dhoopun AR, Yuan Y, Huang S, Zhu C, Ding G, Liu B, Yang T, Zhang A. Mitochondrial dysfunction is an early event in aldosterone-induced podocyte injury. Am J Physiol Renal Physiol 305: F520-F531, 2013.
23. Tomino Y. Mechanisms and interventions in peritoneal fibrosis. Clin Exp Nephrol 16: 109-114, 2012.
24. Tran M, Parikh SM. Mitochondrial biogenesis in the acutely injured kidney. Nephron Clin Pract 127: 42-45, 2014.
25. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10: 210-215, 2010.
26. Wang B, Ding W, Zhang M, Li H, Gu Y. Rapamycin attenuates aldosterone-induced tubulointerstitial inflammation and fibrosis. Cell Physiol Biochem 35: 116-125, 2015.
27. Yuan Y, Huang S, Wang W, Wang Y, Zhang P, Zhu C, Ding G, Liu B, Yang T, Zhang A. Activation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha ameliorates mitochondrial dysfunction and protects podocytes from aldosterone-induced injury. Kidney Int 82: 771-789, 2012.
28. Zhang L, Hao JB, Ren LS, Ding JL, Hao LR. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Lab Invest 94: 839-850, 2014.
29. Zhuang Y, Ding G, Zhao M, Bai M, Yang L, Ni J, Wang R, Jia Z, Huang S, Zhang A. NLRP3 inflammasome mediates albumin-induced renal tubular injury through impaired mitochondrial function. J Biol Chem 289: 25101-25111, 2014.